Characterizing the genetic architecture of drug response using gene-context interaction methods
Open Access
- 4 December 2024
- journal article
- research article
- Published by Elsevier in Cell Genomics
- Vol. 4 (12) , 100722
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institute of Environmental Health Sciences (R01ES029929)
- National Institute of Mental Health (R01MH125252, R01MH122688)
- the Chan Zuckerberg Initiative (CZF2019-002449)
- National Institutes of Health (1R01HG011345, U01HG012079, 2R01HG006399)
- National Heart Lung and Blood Institute (K25HL157603)
- National Institute of General Medical Sciences (R35GM150822)
This publication has 118 references indexed in Scilit:
- Statin Use for the Primary Prevention of Cardiovascular Disease in AdultsJAMA, 2022
- Genome‐Wide Approach to Measure Variant‐Based Heritability of Drug Outcome PhenotypesClinical Pharmacology & Therapeutics, 2021
- From Basic Science to Clinical Application of Polygenic Risk ScoresJAMA Psychiatry, 2021
- Integrating Personalized Medicine With Population Health ManagementJAMA, 2020
- Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese PopulationJAMA Neurology, 2018
- Correcting Systematic Inflation in Genetic Association Tests That Consider Interaction EffectsJAMA Psychiatry, 2014
- Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin TherapyJAMA, 2011
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998